Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988922 | 0.74 | OPRK1 (0.39) | HTR3AUSP30 | |
| SCHEMBL14507265 | 0.73 | DRD4 (0.64) | DRD4DRD2DRD3HTR1AHTR3A | |
| SCHEMBL3985158 | 0.72 | SIGMAR1 (0.48) | CYP2D6 | |
| SCHEMBL3983147 | 0.72 | CYP11B1 (0.48) | DRD4DRD2DRD3KDM4E | |
| Hydrochloric Acid SCHEMBL7037394 | 0.72 | DRD4 (0.63) | DRD4DRD2DRD3HTR1AHTR3A | |
| SCHEMBL5230662 | 0.71 | SIGMAR1 (0.49) | DRD4DRD2DRD3 | |
| SCHEMBL7039513 | 0.69 | DRD4 (1.00) | DRD4DRD2DRD3HTR1AHTR3A | |
| SCHEMBL14507266 | 0.69 | DRD4 (0.64) | DRD4DRD2DRD3HTR1AHTR3A | |
| SCHEMBL14528290 | 0.69 | SIGMAR1 (0.42) | DRD4DRD2DRD3HTR1A | |
| SCHEMBL5228198 | 0.69 | SIGMAR1 (0.42) | DRD4DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | claimed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | claimed |
| JP-2007506723-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | claimed |
| EP-1673372-A1 | NON-AMIDE NONANES | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005030777-A1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | claimed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1674101-B1 | Cinnamates of Benzo[b]pyrano[3,2-h]acridin-7-one, process for preparation thereof and their pharmaceutical composition | SERVIER LAB (FR) | 2007-11-14 | — | — | EP | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1673372-A1 | NON-AMIDE NONANES | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1674101-A1 | Cinnamates of Benzo[b]pyrano[3,2-h]acridin-7-one, process for preparation thereof and their pharmaceutical composition | Les Laboratoires Servier (FR) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030777-A1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | CHRND, CHRNE, CHRM2 | DRD4 570/4885DRD2 113/4885DRD3 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.